Evaluation of a novel monoclonal antibody against tumor-associated MUC1 for diagnosis and prognosis of breast cancer
- PMID: 31588183
- PMCID: PMC6775261
- DOI: 10.7150/ijms.35452
Evaluation of a novel monoclonal antibody against tumor-associated MUC1 for diagnosis and prognosis of breast cancer
Abstract
There is still a great unmet medical need concerning diagnosis and treatment of breast cancer which could be addressed by utilizing specific molecular targets. Tumor-associated MUC1 is expressed on over 90 % of all breast cancer entities and differs strongly from its physiological form on epithelial cells, therefore presenting a unique target for breast cancer diagnosis and antibody-mediated immune therapy. Utilizing an anti-tumor vaccine based on a synthetically prepared glycopeptide, we generated a monoclonal antibody (mAb) GGSK-1/30, selectively recognizing human tumor-associated MUC1. This antibody targets exclusively tumor-associated MUC1 in the absence of any binding to MUC1 on healthy epithelial cells thus enabling the generation of breast tumor-specific radiolabeled immune therapeutic tools. Methods: MAb GGSK-1/30 was used for immunohistochemical analysis of human breast cancer tissue. Its desferrioxamine (Df')-conjugate was synthesized and labelled with 89Zr. [89Zr]Zr-Df'-GGSK-1/30 was evaluated as a potential PET tracer. Binding and pharmacokinetic properties of [89Zr]Zr-Df'-GGSK-1/30 were analyzed in vitro using human and murine cell lines that express tumor-associated MUC1. Self-generated primary murine breast cancer cells expressing human tumor-associated MUC1 were transplanted subcutaneously in wild type and human MUC1-transgenic mice. The pharmacology of [89Zr]Zr-Df'-GGSK-1/30 was investigated using breast tumor-bearing mice in vivo by PET/MRT imaging as well as by ex vivo organ biodistribution analysis. Results: The mAb GGSK-1/30 stained specifically human breast tumor tissue and can be possibly used to predict the severity of disease progression based on the expression of the tumor-associated MUC1. For in vivo imaging, the Df'-conjugated mAb was radiolabeled with a radiochemical yield of 60 %, a radiochemical purity of 95 % and an apparent specific activity of 6.1 GBq/µmol. After 7 d, stabilities of 84 % in human serum and of 93 % in saline were observed. In vitro cell studies showed strong binding to human tumor-associated MUC1 expressing breast cancer cells. The breast tumor-bearing mice showed an in vivo tumor uptake of >50 %ID/g and clearly visible specific enrichment of the radioconjugate via PET/MRT. Principal conclusions: Tumor-associated MUC1 is a very important biomarker for breast cancer next to the traditional markers estrogen receptor (ER), progesterone receptor (PR) and HER/2-neu. The mAb GGSK-1/30 can be used for the diagnosis of over 90% of breast cancers, including triple negative breast cancer based on biopsy staining. Its radioimmunoconjugate represents a promising PET-tracer for breast cancer imaging selectively targeting breast cancer cells.
Keywords: 89Zr; MUC1; breast cancer diagnosis; mAb.
© The author(s).
Conflict of interest statement
Competing Interests: The authors have declared that no competing interest exists.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6775261/bin/ijmsv16p1188g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6775261/bin/ijmsv16p1188g002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6775261/bin/ijmsv16p1188g003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6775261/bin/ijmsv16p1188g004.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6775261/bin/ijmsv16p1188g005.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6775261/bin/ijmsv16p1188g006.gif)
Similar articles
-
89Zr-Labeled AR20.5: A MUC1-Targeting ImmunoPET Probe.Molecules. 2020 May 15;25(10):2315. doi: 10.3390/molecules25102315. Molecules. 2020. PMID: 32429033 Free PMC article.
-
Light-Induced Radiosynthesis of 89Zr-DFO-Azepin-Onartuzumab for Imaging the Hepatocyte Growth Factor Receptor.J Nucl Med. 2020 Jul;61(7):1072-1078. doi: 10.2967/jnumed.119.237180. Epub 2020 Jan 10. J Nucl Med. 2020. PMID: 31924725 Free PMC article.
-
Synthesis and Evaluation of a Zr-89-Labeled Monoclonal Antibody for Immuno-PET Imaging of Amyloid-β Deposition in the Brain.Mol Imaging Biol. 2016 Aug;18(4):598-605. doi: 10.1007/s11307-016-0935-z. Mol Imaging Biol. 2016. PMID: 26846128
-
Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?Front Pharmacol. 2016 May 24;7:131. doi: 10.3389/fphar.2016.00131. eCollection 2016. Front Pharmacol. 2016. PMID: 27252651 Free PMC article. Review.
-
89Zr-Labeled p-isothiocyanatobenzyl-desferrioxamine B (Df-Bz-NCS)–conjugated panitumumab, a fully human monoclonal antibody directed against the extracellular domain III of the epidermal growth factor receptor.2012 May 4 [updated 2012 Jun 21]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2012 May 4 [updated 2012 Jun 21]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 22741179 Free Books & Documents. Review.
Cited by
-
Identification and comprehensive analysis of epithelial-mesenchymal transition related target genes of miR-222-3p in breast cancer.Front Oncol. 2023 Jul 20;13:1189635. doi: 10.3389/fonc.2023.1189635. eCollection 2023. Front Oncol. 2023. PMID: 37546414 Free PMC article.
-
Advances in PET/CT Imaging for Breast Cancer.J Clin Med. 2023 Jul 7;12(13):4537. doi: 10.3390/jcm12134537. J Clin Med. 2023. PMID: 37445572 Free PMC article. Review.
-
MUC1 Glycopeptide Vaccine Modified with a GalNAc Glycocluster Targets the Macrophage Galactose C-type Lectin on Dendritic Cells to Elicit an Improved Humoral Response.J Am Chem Soc. 2023 Jun 21;145(24):13027-13037. doi: 10.1021/jacs.2c12843. Epub 2023 Jun 6. J Am Chem Soc. 2023. PMID: 37279388 Free PMC article.
-
Expression of MUC1 in different tumours and its clinical significance (Review).Mol Clin Oncol. 2022 Nov 1;17(6):161. doi: 10.3892/mco.2022.2594. eCollection 2022 Dec. Mol Clin Oncol. 2022. PMID: 36479256 Free PMC article. Review.
-
Advances in MUC1-Mediated Breast Cancer Immunotherapy.Biomolecules. 2022 Jul 6;12(7):952. doi: 10.3390/biom12070952. Biomolecules. 2022. PMID: 35883508 Free PMC article. Review.
References
-
- Braden A, Stankowski R, Engel J, Onitilo A. Breast Cancer Biomarkers: Risk Assessment, Diagnosis, Prognosis, Prediction of Treatment Efficacy and Toxicity, and Recurrence. Curr Pharm Des [Internet] 2014;20(30):4879–98. - PubMed
-
- Alwan NAS, Tawfeeq FN, Muallah MH, Sattar SA, Saleh WA. The Stage of Breast Cancer at the Time of Diagnosis: Correlation with the Clinicopathological Findings among Iraqi Patients. J Neoplasm [Internet]; 2017. p. 2. (3:11):1-9.
-
- Gaidzik N, Kaiser A, Kowalczyk D, Westerlind U, Gerlitzki B, Sinn HP. et al. Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor tissues. Angew Chem Int Ed Engl [Internet] 2011;50(42):9977–81. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous